This continuing education self-study monograph, “Today's Perspectives In Adult Glioblastoma,” is certified for physicians, pharmacists, and registered nurses.
To Download
MEDIUM: MONOGRAPH
Release date: October 27, 2010
(Continuing education credit is no longer available for this activity.)
CONTENTS
- Introduction: A Brief History of Glioblastoma Treatment
- Glioblastoma Review
- Presentation and Diagnosis
- First-Line Treatment of Adult Glioblastoma
- Recurrent Glioblastoma
- Conclusion: Steps Forward in Glioblastoma Care
- References
FACULTY REVIEWER
Marc C. Chamberlain, MD
Professor, Neurology & Neurological Surgery
Department of Neurology & Neurological Surgery
Chief, Division of Neuro-Oncology
University of Washington
Affiliate Member
Fred Hutchinson Cancer Research Center
Seattle, Washington
TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, pharmacists, registered nurses, and all other healthcare professionals who are involved in the care of patients with glioblastoma.
STATEMENT OF NEED
Adult glioblastoma is a condition that is associated with an extremely poor prognosis. Treatment of adult glioblastoma, which includes surgery, chemotherapy, and radiation therapy, can prolong survival in some patients.¹ In particular, the addition of temozolomide to adult glioblastoma treatment regimens has resulted in improved outcomes in these patients.¹ However, 2-year survival rates associated with this condition are still low (<25%), and recurrence or tumor progression is frequently encountered.² Fortunately, novel biologic targets are being identified that may guide future therapy for adults with this condition.³
¹Ashby LS, Ryken TC. Neurosurg Focus. 2006;20(4):E3.
²Stupp R, et al. N Engl J Med. 2005;352:987-996.
³Van Meir EG, et al. CA Cancer J Clin. 2010;60:166-193.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe the diagnostic assessment of glioblastoma
- Outline the treatment of adult glioblastoma, including surgery, radiation therapy, and chemotherapy
- Identify treatment challenges in recurrent glioblastoma
- Summarize emerging treatment options that offer promise for improved outcomes in adults with glioblastoma
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of continuing education (CE) activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
CONTINUING EDUCATION
METHOD OF PARTICIPATION
There are no fees for participating and receiving continuing medical education (CME) credit for this activity. PIM supports Green CME by offering your request for credit online. If you wish to receive acknowledgment for completing this activity, please adhere to the following steps during the period of October 27, 2010, through October 27, 2011: Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, and 3) complete the post-test and evaluation on www.cmeuniversity.com. Click on “Find Post-Test/Evaluation by Course” on the navigation menu, and search by course ID 7198. Upon registering and successfully completing the post-test (score of 70% or better) and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year. Additional educational activities offered by Robert Michael Educational Institute LLC can be found at www.RMEI.com
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Robert Michael Educational Institute LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour
(0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number -0809-9999-10-167-H01-P).
Type of Activity: Knowledge
ACPE release date: May 20, 2010
If you have received credit for UAN 0809-9999-10-091-L01-P, you are not eligible for this activity.
NURSING CONTINUING EDUCATION
CREDIT DESIGNATION
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine (PIM).
CNA/ANCC
PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CALIFORNIA BOARD OF REGISTERED NURSING
PIM is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.2 contact hours.
STATEMENT OF SUPPORT
This activity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine, and is supported by an educational grant from Merck.
FEE INFORMATION
There is no fee for this educational activity.
|
Additional educational activities offered by Robert Michael Educational Institute LLC can be found at www.RMEI.com or by calling toll-free to 866-770-RMEI.
